Mizuho Lowers Medtronic (MDT) Target Ahead of Q1, Maintains Positive View

Medtronic plc (NYSE:MDT) is included among the Early Retirement Portfolio: Top 15 Stocks to Buy.

Mizuho Lowers Medtronic (MDT) Target Ahead of Q1, Maintains Positive View

On April 13, Mizuho lowered the firm’s price recommendation on Medtronic plc (NYSE:MDT) to $120 from $125. It kept an Outperform rating on the shares. The firm made the adjustment as it updated estimates and price targets across several names in its medical devices and diagnostics coverage ahead of Q1 earnings.

On April 7, Citi analyst Joanne Wuensch also lowered the price target on Medtronic to $110 from $117, while maintaining a Buy rating. The changes were part of a broader Q1 preview for the medical technology group. The analyst said the “walls of worry are high” heading into earnings, with the sector seeing significant multiple compression, according to a research note. Citi also removed iRhythm and Medtronic as top picks, naming Edwards Lifesciences and Intuitive Surgical as its new top choices.

Medtronic plc (NYSE:MDT) is based in Ireland and provides healthcare technology solutions. Its products are organized across four main segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes.

While we acknowledge the risk and potential of MDT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MDT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 14 Value Stocks with Highest Dividends and 15 Cash-Rich Dividend Stocks to Invest In Right Now

Disclosure: None. Follow Insider Monkey on Google News.